Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Stopped Termination of the study was made after a full review of program data and assessment of the current risk-benefit profile.

Conditions

• Advanced Solid Tumors
• Cancer
• Advanced Solid Malignancies

Interventions

• DRUG: AZD7762
• DRUG: Irinotecan

Sponsor

AstraZeneca